STP-C, an Oncoprotein of *Herpesvirus saimiri* Augments the Activation of NF-κB through Ubiquitination of TRAF6

Young-Hwa Chung, Byung Hak Jhun, Su-Chak Ryu, Heui-Soo Kim, Cheol-Min Kim, Bong-Seok Kim, Young-Ok Kim and Sang Jun Lee

1Department of Nanomedical Engineering, 2Department of Nanomaterials Engineering BK21 Nano Fusion Technology Team, Joint Research Center of PNU-Fraunhofer IGB, Pusan National University, Miryang 627-706, Korea
3Department of Biology, 4Department of Biochemistry, Pusan National University, Busan 609-735, Korea
5Biotechnology Research Center, National Fisheries Research & Development Institute, Busan 619-902, Korea

Received 28 September 2006, Accepted 15 December 2006

*Herpesvirus saimiri* (HVS), a member of the γ-herpesvirus family, encodes an oncoprotein called Saimiri Transforming Protein (STP) which is required for lymphoma induction in non-human primates. Previous study has shown that STP-C, an oncoprotein of HVS, activates NF-κB signaling pathway. However, the detailed mechanism of STP-C-mediated NF-κB activation has not been reported yet. We first report that STP-C interacts with TRAF6 protein in vivo and in vitro and further investigation shows that Glu12 residue of STP-C is critical for binding to TRAF6. Introduction of ubiquitin together with STP-C augments NF-κB activity compared to that of STP-C expression alone. STP-C expression further induces ubiquitination of endogenous TRAF6. In addition, either a deubiquitination enzyme, CYLD or a dominant negative E2-conjugation enzyme reduced NF-κB activity in spite of the presence of STP-C, suggesting that the interaction between STP-C and TRAF6 induces ubiquitination of TRAF6. NF-κB activation by STP-C through the ubiquitinated TRAF6 causes the increased production of IL-8, an inflammatory chemokine and the enhanced expression of costimulatory molecule ICAM, which might ultimately contribute cellular transformation by the exposure of HVS-infected cells with inflammatory microenvironment and chronic activation.

**Keywords:** *Herpesvirus saimiri*, NF-κB, STP-C oncoprotein, TRAF6, Ubiquitin

**Introduction**

Despite of a structural homology between TNF-α receptor associated factor (TRAF) molecules, each TRAF harbors a distinct biological function involved in cell death, survival, and immune responses (Bradley and Pober, 2001; Chung et al., 2002; Lee and Lee, 2002). TRAF family members 2, 5, and 6 share functions to activate Jun-N terminal kinase (JNK) and p38 MAP kinase (Baud et al., 1999; Dempsey et al., 2003), whereas neither TRAF3 nor TRAF4 activates these pathways (Chung et al., 2002; Ely and Li, 2002). Recent studies have shown that the structural determinant of the TRAF6-binding motif; a PxxxL/E/D (Acidic residue/hydrophobic residue) is distinct from TRAF2-binding motif; a PxxQxT/S with crystallization (Ye et al., 2002). Furthermore, gene knockout studies have proposed that TRAF2 is responsible for JNK activity and TRAF6 is critical for NF-κB signaling (Lomaga et al., 1999; Nguyen et al., 1999). Thus, TRAF5 functions as an adaptor protein for various receptors such as IL-1/Toll-like-, TNF-related activation-induced cytokine (TRANCE)-, and CD40-receptor, leading to NF-κB activation (Jabara et al., 2002).

Ubiquitin (Ub) is a globular protein with 76 amino acid residues that is highly conserved throughout eukaryotes, with three amino acid changes from yeast to human (Pickart, 2001). The classical view of ubiquitination is that ubiquitination targets proteins for degradation by a multi-subunit, ATP-dependent 26 proteosome (Pickart, 2001; Lee and Yu, 2005). Conjugation involves the sequential actions of activating (E1), conjugating (E2), and ligase (E3) enzymes (Pickart, 2001; Pickart, 2004). Poly-ubiquitination chain linked through K48 on Ub targets a protein for proteosome degradation although poly-chains of Ub can be formed through K11 and K29 in vivo (Chau et al., 1989; Peng et al., 2003). Apparently, poly-Ub chain linked through K63 is not a proteosome-targeting...
signal. Instead, K63 linkage on Ub is important for DNA repair and IkB kinase activation although the detailed mechanism has not been illustrated (Deng et al., 2000; Hoeg et al., 2002).

Due to the induction of lymphoma in New World primates (Jung et al., 1999; Damiania et al., 2000), studies on Herpesvirus saimiri (HVS), a member of γ-herpesvirus family have been extensively performed as an alternative animal model for studies on Epstein Barr Virus (EBV) or Kaposi’s sarcoma-associated herpesvirus (KSHV)-mediated pathogenic disease of human (Jung and Desrosiers, 1991; Jung and Desrosiers, 1995). HVS can be further subclassified into three subgroups (HVS-A, B, and C) on the basis of the extent of DNA sequence divergence at the left end of L-DNA (Medveczky et al., 1984). Thus, mutational analyses on the gene products designated with stimul function protein (STP-A, or C) have demonstrated that STP is not required for viral replication but for immortalization (Murthy et al., 1989). Further studies on STP-C-mediated oncogenesis have revealed that STP-C interacts with not only oncoprotein Ras molecule, leading to MAP kinase activation (Jung and Desrosiers, 1995) but also TRAF6, 3 and 5 molecules for NF-κB activation (Lee et al., 1999).

Although previous study has shown that STP-C activates NF-κB signaling pathway (Lee et al., 1999), the detailed mechanism of STP-C-mediated NF-κB activation has not been reported yet. Herein, we first report that STP-C binds to TRAF6 in vivo and in vitro, leading to NF-κB activation. The expression of STP-C induced ubiquitination of endogenous TRAF6. Blockage of TRAF6 ubiquitination by CYLD, a deubiquitination enzyme or a dominant negative-E2 conjugation enzyme; Ubc13 (C87A) drastically diminished STP-C-mediated NF-κB activation. Finally, STP-C expression induced the production of IL-8 and ICAM expression through TRAF6 ubiquitination, which might ultimately contribute cellular transformation by the exposure of HVS-infected cells with inflammatory microenvironment and chronic activation.

Materials and Methods

Cell culture and transfection. Human embryonic kidney (HEK) 293 T cells, Flp-In Trex-293 cells expressing the tetacycline repressor protein (Invitrogen), and Hela cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. BJAB B lymphocytes and Jurkat T lymphocytes were cultured in RPMI-1640 supplemented with 10% FBS and 1% penicillin and streptomycin. HEK 293T cells and Hela cells were plated at 5 x 10⁴ per 100-mm-diameter plate 24 h before transfection and the cells were transfected with 8 to 15 μg of DNA using calcium phosphate precipitation method (Clontech) and Lipofectam in (Invitrogen) with glutathione Sepharose 4B beads as recommended by the manufacturer (Amersham). At 48 h after transfection with TRAF6 vector, HEK 293 T cells were lysed with binding buffer (20 mM Tris[ph7.5]) containing 0.1 mM NaVO₃, 1 mM NaF, and protease inhibitors (leupeptin, aprotinin, phenylmethylsulfonyl fluoride, and bestatin). For immunoblotting, proteins from whole cell lysate were resolved by 10% or 12% SDS-PAGE and transferred to nitrocellulose membranes. Primary antibodies were used at 1:1,000 or 1:2,000 dilutions, and secondary antibodies were used at 1:2,000 dilution 6% nonfat dry milk. After final washing, nitrocellulose membranes were exposed for an enhanced chemiluminescence assay.

In vitro GST pull-down assay. The GST and GST-STP-C recombinant protein were purified from Escherichia coli BL21 (Invitrogen) with glutathione Sepharose 4B beads as recommended by the manufacturer (Amersham). At 48 h after transfection with TRAF6 vector, HEK 293 T cells were lysed with binding buffer (20 mM Tris[pH 7.5], 150 mM NaCl, 1% Triton X-100, 1% Protease inhibitor cocktail solution (Sigma-Aldrich) and mixed with 10 μg of the GST fusion protein for 2 h at 4°C. Then, glutathione Sepharose 4B beads were extensively washed and subjected to 10% SDS-PAGE, followed by an immunoblot assay.

NF-κB reporter assay. HEK 293 T cells or Hela cells were transfected with WT or its mutant STP-C vector together with NF-κB-luciferase report vector by the calcium phosphate precipitation method or Lipofectam in (Invitrogen). To normalize transfection efficiency, the pRK-βgal vector that expresses β-galactosidase from a phosphoglucomokinase promoter, was included in the transfection mixture. At 48 h post-transfection, cells were washed with cold phosphate-buffered saline (PBS) and lysed in lysis solution (25 mM Tris[pH 7.8], 2 mM EDTA, 2 mM DTT, 10% glycerol, and 1% Triton X-100). Luciferase activity was measured with a luminometer by using a luciferase assay kit (Promega).

Treatment of siRNA against TRAF6. Hela cells were plated at equal densities in 6 well plate (2 x 10⁴ cells/well) and treated with siRNAs against TRAF6 or a non-specific control at 24 h after transfection with STP-C and NF-κB reporter vectors using X-tremeGene siRNA transfection reagent (Roche) as described by the manufacturer’s instruction. Sequences used were as follows. For the control, siRNA control: 5'-CCU ACG CCA CCA AUU UCG UG-3' as sense and 5'-ACG AAA UUG GUG GCG UAG G-3' as antisense were synthesized and for TRAF6, the siRNAs were used; 5'-CGU UGC UGC AUC AUA GGC A-3' as sense and 5'-UGC...
CAU UGA UGC AGC ACA G-3' as antisense. The cells were harvested for immunoblotting and NF-κB reporter assay at 24 h after siRNA treatment.

Flow cytometry. BJAB B cells or Jurkat T cells (1 x 10^6 cells) were washed with RPMI-1640 medium supplemented with 10% FBS and stained with a phycoerythrin(PE)-conjugated ICAM monoclonal Antibody (Becton Dickson) at 4°C for 30 min. After washing with RPMI-1640 medium supplemented with 10% FBS, and the flow cytometry was performed by FACS (Becton Dickson).

Enzyme-linked immunosorbent assay (ELISA). At 48 h after induction of WT or mutant STP-C expression by deoxycycline (2 µg/ml), the cell supernatants were harvested and used for the measurement of IL-8 production using Pharmingen ELISA kit (Becton Dickson).

Results

Enhanced polyubiquitination due to presence of STP-C augments NF-κB activity. Recently, it has been reported that a poly-ubiquitination of a protein indicates not only protein degradation in the 26S proteosome but also activation of NF-κB (Deng et al., 2000; Goldberg, 2003). Expression of STP-C, an oncoprotein of HVS has been shown to increase NF-κB activity (Lee et al., 1999). These series of evidence prompted us to explore whether expression of STP-C induces poly-ubiquitination of proteins, leading to activation of NF-κB.

First of all, to examine whether presence of STP-C induces poly-ubiquitination of proteins HEK 293T cells were transfected with Ubiquitin (Ub) expression vector along with or without STP-C expression vector. As shown in Fig. 1A, the expression of Ub alone induced a weak poly-ubiquitination of cellular proteins, which is further enhanced by co-expression of Ub and STP-C. Co-expression of Ub and protein-linking integrin-associated protein and cytoskeleton (PLIC-1), a cargo protein involved in a link between the ubiquitinated protein (Kneussel, 2002) and the proteosome machinery, also increased poly-ubiquitination as seen in co-expression of Ub and STP-C.

Next, when NF-κB activity was examined in the expression of STP-C or PLIC-1 together with Ub, co-expression of STP-C and Ub increased a drastic activity of NF-κB, whereas co-expression of PLIC-1 and Ub did not affect any activity of NF-κB (Fig. 1B). This result implies that poly-ubiquitination by the presence of STP-C is qualitatively different from that by the presence of PLIC-1. Of interest, co-expression of STP-C and Ub showed much higher activity of NF-κB, compared to that of STP-C expression alone. The result suggests that an enhanced poly-ubiquitination due to expression of STP-C augments NF-κB activity.

STP-C interacts with TRAF6 in vivo and in vitro. Because STP-C has been reported to interact with TRAF2, 3, and 5 using the binding motif of PxQxT/S (Lee et al., 1999), we examined whether STP-C carries TRAF6 binding motif such as PxExEΦ or not. We found that STP-C oncoprotein indeed contains a candidate TRAF6-binding motif P11IEETGD17, although it is not exactly matched to the published one (Ye et al., 2002). Therefore, we pursued whether STP-C oncoprotein interacts with TRAF6 in vivo and in vitro. HEK 293 T cells were transfected with STP-C, TRAF6 or both STP-C and TRAF6, and the cell lysates were immunoprecipitated with anti-STP-C (109) antibodies (Jung and Desrosiers, 1995) and blot with anti-flag antibody for the detection of TRAF6. TRAF6 protein was only detected in the co-expression of STP-C and TRAF6 (Fig. 2A), indicating that STP-C interacts

Fig. 1. Augmentation of NF-κB activity by enhanced ubiquitination due to the expression of STP-C. (A) After pEF1-STP-C and pCMV4-Flag-PLIC-1 with or without pEF-HA-Ub were transfected into HEK 293T cells, the cell lysates of ubiquitination were detected with an anti-HA antibody, β-Tubulin was used for the loading control. (B) After transfection with STP-C (3 µg) and PLIC-1 (3 µg) in the presence or absence of Ub (2 µg), NF-κB lucifense activity was measured. Transfection efficiency was normalized with β-galactosidase activity.
with TRAF6 \textit{in vivo}. In addition, to examine whether STP-C interacts with TRAF6 \textit{in vitro}, GST and GST-STP-C recombinant protein were expressed and purified as described previously (Lee et al., 1999). TRAF6 from the cell lysate was pulled down with GST-STP-C or GST. As seen in Fig. 2B, GST-STP-C did precipitate TRAF6 whereas GST did not. Therefore, the results indicate that STP-C specifically binds to TRAF6 \textit{in vivo} and \textit{in vitro}.

Furthermore, in order to pursue the search of a crucial residue in STP-C for the interaction with TRAF6, Glu12 residue of STP-C was substituted with Ala, designated as E12A. We performed an immunoprecipitation with anti-STP-C antibodies using cell lysates of co-transfection with TRAF6 and WT, or E12A mutant of STP-C, and thereafter followed an immunoblotting with anti-flag antibody for the detection of TRAF6. WT of STP-C interacted with TRAF6 but E12A mutant lost the ability of binding to TRAF6 (Fig. 2C). The result clearly indicated that Glu12 residue of STP-C is necessary for binding to TRAF6. The importance of the interaction between STP-C and TRAF6 was further addressed. WT or E12A of STP-C was transfected with NF-κB reporter vector and measured for NF-κB activity. E12A mutant of STP-C, losing the binding ability of TRAF6 exhibited a drastically reduced NF-κB activity, compared to that of WT (Fig. 2D). Therefore, the results indicate that Glu12 residue of STP-C is important for the interaction with TRAF6 and NF-κB activation.

Ubiquitination of TRAF6 by the expression of STP-C is critical for the activation of NF-κB. Because TRAF6 protein contains Zinc-finger and RING finger domains at the N-terminus and TRAF C domain at the C-terminus as similar as structures of the other TRAF proteins (Bradley and Pober, 2001; Wajant and Scheurich, 2001; Chung et al., 2002), we explored a role of RING finger motif for the ubiquitination. An extensive ubiquitination of WT TRAF6 was detected in the co-expression of Ub and TRAF6, whereas ubiquitination of TRAF6 mutant, depleted of RING finger domain did not occur. The result indicates that RING finger domain is involved in the ubiquitination of TRAF6, which is critical for E3 Ub ligase (Wang et al., 2001). Furthermore, to examine whether the presence of STP-C induces ubiquitination of endogenous TRAF6, HEK 293T cells were co-transfected with STP-C and Ub vectors. Endogenous TRAF6 was immunoprecipitated using anti-TRAF6 antibody from the cell lysate and ubiquitination of endogenous TRAF6 was detected from TRAF6 immune complex in the presence of STP-C. The result proposes that STP-C increases ubiquitination of TRAF6, resulting in enhancement of NF-κB activity. Furthermore, we attempted to suppress endogenous TRAF6 activity.
expression using its siRNA to clarify a role of TRAF6 in STP-C-mediated NF-κB activation. When the expression of TRAF6 was inhibited by its siRNA, we found significantly reduced NF-κB activity in spite of the presence of STP-C.

To test our proposal that increased ubiquitination of TRAF6 due to the expression of STP-C augments NF-κB activity, we also decreased TRAF6-mediated NF-κB activity (Fig. 3D). Introduction of either CYLD or Ubc13 (C87A) in STP-C expression drastically diminished NF-κB activity as seen in TRAF6 expression (Fig. 3D). Therefore, the result supports that increased ubiquitination of TRAF6 due to the expression of STP-C augments NF-κB activity.

**Interaction of STP-C with TRAF6 is important for the production of IL-8 and the expression of ICAM.** To examine a biological role of the interaction of STP-C with TRAF6, we generated 293 cell lines expressing tetracycline-inducible WT or E12A mutant of STP-C and transiently expressed WT or E12A mutant of STP-C in BJAB B and Jurkat T lymphocytes. When doxycycline, an analogue of tetracycline was added, the expression of WT STP-C dramatically increased NF-κB activity while the
expression of E12A mutant did not (Fig. 4A). This result was exactly correlated with IL-8 production; the expression of STP-C produced a significant amount of IL-8, whereas the expression of E12A mutant did not. The result indicates that interaction of STP-C with TRAF6 is important for the production of IL-8, an inflammatory chemokine and angiogenesis factor.

WT or E12A mutant of STP-C, subcloned to pT race vector carrying GFP was transfected to BJAB B and Jurkat T lymphocytes, and ICAM expression was measured among GFP positive cell populations using FACS. As seen in Fig. 4B, the transient expression of WT STP-C induced ICAM expression on BJAB and Jurkat T cells. However, the expression of E12A mutant reduced the level of ICAM expression, compared to that of WT STP-C. These results suggest that NF-κB activation by the expression of STP-C through TRAF6 plays a crucial role in the production of an angiogenesis factor and a costimulatory molecule.

Discussion

In addition to the role of Ub in protein degradation, Ub plays an essential role in IKK activation by TRAF proteins (Deng et al., 2000; Shi and Kehrl, 2003). During cytokine signaling such as TNF-α and IL-1β, TRAF2 and TRAF6 are ubiquitinated and they act as E3 ligases that function together with Ube13/Uev1A as a conjugation enzyme to catalyze the synthesis of a unique poly-Ub chain linked through K63 of Ub. Furthermore, it has been reported that ubiquitinated TRAF2 and TRAF6 are pre-requisite for NF-κB signaling (Deng et al., 2000; Shi and Kehrl, 2003; Habellah et al., 2004). Herein, we observed that STP-C expression induces poly-ubiquitination of endogenous TRAF6 as seen in cytokine IL-1β signaling. We thus believe that poly-ubiquitinated TRAF6 induced by STP-C facilitates to deliver a signal to a downstream molecule such as TAK1, resulting in NF-κB activation. Therefore, we propose that STP-C acts like a TNF receptor superfamily, particularly IL-1β/Toll-like receptor with a ligand-independent manner, which leads to a constitutive activation of NF-κB.

Importance of ubiquitinated TRAF2 or TRAF6 during cytokine signaling has been addressed by CYLD, a tumor suppressor cylindromatosis protein, which acts as a deubiquitination enzyme. The previous studies demonstrate that CYLD facilitates the disassembly of K63-linked poly-Ub chains on TRAF2 and TRAF6, resulting in the inhibition of IKK and subsequent NF-κB activation by agents such as TNF-α, IL-1 and phorbol ester (Kovalenko et al., 2003; Trompouki et al., 2003). We indeed observed that introduction of CYLD inhibits STP-C-mediated NF-κB activation. Accordingly, we propose that ubiquitination of TRAF6 is necessary for the NF-κB activation mediated by STP-C. However, due to a result of a long exposure of the blot to detect ubiquitination of TRAF6 in Fig. 3B, we could not exclude a possibility that a small portion of ubiquitinated TRAF6 might lead to its degradation and recycling, which may be undetectable with a conventional method. Therefore, a detailed biochemical mechanism for poly-ubiquitination of TRAF6 by STP-C remains as assignment to be resolved.

It is interesting that NF-κB is a common target for
oncogenic viral proteins including Tax protein of human T lymphocytic leukemia virus (HTLV)-1, Core protein of Hepatitis C virus, and latent membrane protein (LMP)1 of EBV (Kaye et al., 1996; Yin et al., 1998; Yoshida et al., 2001). In addition, an elevated NF-κB expression and inflammatory cytokines have been frequently found in clinical tumor tissues (Wissink et al., 1997; Griffin, 2001; Helbig et al., 2008). Cancerous cells furthermore migrate into vessel walls through various adhesion molecules including ICAM-1, VCAM-1, and ELAM-1, which are up-regulated by NF-κB expression (van de Stolpe and van der Saag, 1996). We herein showed that activated NF-κB by STP-C induces to increase the expression of IL-8 and ICAM. We thus propose that elevated NF-κB induces the extension of host cell survivals, upon HVS infection into host cells. HVS-infected cells are further exposed under a chronic inflammatory environment and continuous activation through costimulatory molecules with ligand independent manner, which may ultimately contribute cellular transformation.

Acknowledgments. We thank Dr. Jae Jung (Harvard Medical School, USA) for valuable comments and materials. This work was supported by 2006 PNU-IGB Joint Research Center Grant of Pusan National University.

References


